Sacubitril/valsartan compared to ramipril in high risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: Insight from PARADISE MI trial

Back

ESC Professional Premium Access

Sacubitril/valsartan compared to ramipril in high risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: Insight from PARADISE MI trial

Session: Neprilysin inhibition: news and nuggets

Topic: Pharmacotherapy

Speaker: Professor M. Schou (Gentofte, DK)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Morten Schou

Herlev-Gentofte University Hospital, Gentofte (Denmark)

1 presentation

0 follower

5 more presentations in this session

Effects of sacubitril-valsartan on clinical, echocardiographic and polygraphic parameters in patients affected by heart failure with reduced ejection fraction and sleep apnea

Speaker: Doctor G. Armentaro (Catanzaro, IT)

ARNI effects in HFrEF. Risk reduction beyond LVEF

Speaker: Doctor A. Boehmer (Wiesbaden, DE)

Prevalent and incident anaemia in PARADIGM-HF and effect of sacubitril/valsartan

Speaker: Doctor J. Curtain (Glasgow, GB)

Effects of angiotensin receptor-neprilysin inhibitors (ARNIs) on the glucose and fat metabolism biomarkers leptin and fructosamin

Speaker: Doctor B. Ohnewein (Salzburg, AT)

Effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure

Speaker: Doctor V. Cassano (Catanzaro, IT)

Access the full session

Neprilysin inhibition: news and nuggets

Speakers: Professor M. Schou, Doctor G. Armentaro, Doctor A. Boehmer, Doctor J. Curtain, Doctor B. Ohnewein...

Access

Video

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources